223 related articles for article (PubMed ID: 28056160)
1. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
[TBL] [Abstract][Full Text] [Related]
2. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
3. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
[TBL] [Abstract][Full Text] [Related]
5. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
[TBL] [Abstract][Full Text] [Related]
8. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
[TBL] [Abstract][Full Text] [Related]
9. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
Xing L; Huang A
Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
[TBL] [Abstract][Full Text] [Related]
10. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
11. Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.
Guilinger JP; Archna A; Augustin M; Bergmann A; Centrella PA; Clark MA; Cuozzo JW; Däther M; Guié MA; Habeshian S; Kiefersauer R; Krapp S; Lammens A; Lercher L; Liu J; Liu Y; Maskos K; Mrosek M; Pflügler K; Siegert M; Thomson HA; Tian X; Zhang Y; Konz Makino DL; Keefe AD
Bioorg Med Chem; 2021 Jul; 42():116223. PubMed ID: 34091303
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
[TBL] [Abstract][Full Text] [Related]
13. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
[TBL] [Abstract][Full Text] [Related]
14. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
16. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
[TBL] [Abstract][Full Text] [Related]
18. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
19. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
20. Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library.
Kim D; Sun Y; Xie D; Denton KE; Chen H; Lin H; Wendt MK; Post CB; Krusemark CJ
Molecules; 2019 Jul; 24(15):. PubMed ID: 31366048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
